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ABSTRACT
OBJECTIVE: The objective of this EBM review is to determine whether or not “Does
adalimumab effectively treat moderate to severe chronic plaque psoriasis in adults?”
STUDY DESIGN: This review is based on two randomized controlled trials and one
retrospective study. The studies compared the efficacy of adalimumab in reducing the
body surface area affected by plaque psoriasis.
DATA SOURCES: All articles used in this review are peer reviewed journals, published
in English, and found using PubMed and Ebscohost.
OUTCOMES MEASURED: For all studies, the effectiveness of adalimumab on
moderate to severe plaque psoriasis was evaluated using Psoriasis Area Severity Index
(PASI) and Physician’s Global Assessment of hand and/or feet (hfPGA).
RESULTS: All studies concluded that adalimumab used as monotherapy, or in
combination with topical calciptriol/betamethasone proved to be effective in treating
moderate to severe chronic plaque psoriasis.
CONCLUSIONS: ADA + C/B resulted in more rapid improvement during the first four
weeks of treatment vs. ADA monotherapy. There was no statistical difference in the
PASI 75 response at week 16 but there was statistical significance in the PASI 90
response. Regardless of patient demographics at baseline, ADA proved to be effective.
All treatment regimens were well tolerated.
KEY WORDS: Adalimumab, psoriasis, biological therapy
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INTRODUCTION
Psoriasis is a chronic, relapsing, inflammatory skin condition that varies in
severity and body surface area (BSA) affected. It can manifest from a few localized
lesions to complete body coverage. Furthermore it can primarily involve the hands, feet,
fingernails and toenails1. The plaque type of psoriasis is the most common, although
several clinical variants of psoriasis are documented. The pathophysiology of plaque
psoriasis is suggested to be immune with pathology occurring in both the epidermal and
dermal layers of the skin1. It is characterized by sharply defined red plaques covered with
silvery scales. It is often asymptomatic, but itching may occur and can be severe2. Plaque
psoriasis occurs worldwide, and its prevalence varies with race, geography and
environmental factors such as sun exposure, trauma, smoking and alcohol consumption.
However, family history has had the largest affect on predicting disease occurrence2.
To Physician Assistants who practice in general medicine and dermatologic
specialties, it is a common condition seen affecting 1-3% of the population in the United
States1, 2. Furthermore, plaque psoriasis treatment estimates an annual cost of $11,029
and $26,708 for patients treated with conventional systemic agents and biologics
respectively3. There is not an exact estimate available for the amount of health care visits
per year for the treatment of plaque psoriasis, but the annual treatment cost across the
United States is estimated at $11 billion dollars3.
Plaque psoriasis is a well-known and studied pathology; however, as stated
previously, the exact pathophysiology is only suggested to be immune mediated. The
exact cause remains a focal point of research. Psoriasis impacts patients both physically
and psychologically. Patients report a reduction in physical and mental function
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comparable to that seen in diseases such as cancer, arthritis, heart disease and depression
leading to marked impairment in quality of life4. The inflammatory process of psoriasis
is linked to a variety of comorbidities such as arthritis, cardiovascular complications,
malignancies, depression, anxiety, and obesity2, 4. Psoriatic arthritis is a chronic
inflammatory arthropathy often associated with psoriasis affecting between 20% and 30%
of patients with psoriasis4. One recent population based cohort study confirmed that
patients with psoriasis are at an increased risk of myocardial infarction and stroke with an
increase of 6.2% in the 10 year risk rate compared to the normal population4.
Additionally, psoriasis patients are an increased risk to melanoma and non-melanoma
skin cancers. The co-morbidities of psoriasis not only impact the patient’s daily life in the
short term but prolonged disease may result in cumulative impairment of many facets of
life including financial status, professional careers, and reduced life expectancy4.
There are a variety of therapeutic options available in the treatment of psoriasis
and are chosen according to the extent of BSA affected, and the presence of other
findings such as associated arthritis. In limited disease affecting less than 10% BSA, high
to ultra-high potency topical corticosteroids (Clobetasol, Betamethasone) are the
mainstay of treatment. The addition of a Vitamin D analog such as calcitriol ointment
may be indicated in limited disease. In moderate disease affecting 10-30% of BSA,
patients are frequently treated with UV phototherapy. Systemic agents such as
methotrexate and cyclosporine may be indicated as well. Established systemic therapies
are typically indicated if the disease is severe or refractory to topical treatment1, 2,4.
Applicable to this review, tumor necrosis factor (TNF) inhibitors such as adalimumab
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(ADA) has been approved in the United States for moderate to severe chronic plaque
psoriasis.
The method proposed and studied by this particular review is treatment with
subcutaneous ADA. The injectable TNF inhibitor is used as mono-therapy in hopes that
inhibiting a major inflammatory mediator will improve the erythematous, scaly, itchy
lesions and BSA affected by moderate to severe chronic plaque psoriasis.
OBJECTIVE
The objective of this EBM review is to determine whether or not ADA effectively
treats moderate to severe chronic plaque psoriasis in adults.
METHODS
Two double blind, randomized, placebo control trials, and one retrospective study
were included in this EBM review. The studies were selected based on several criteria
including population, interventions used, comparison groups, and outcomes measured. In
all three studies, the population studied were patients 18 years of age or older with a
history of moderate to severe plaque psoriasis with a baseline Psoriasis Area Severity
Index (PASI) greater than or equal to 10 or a baseline of at least 3 on the Physician’s
Global Assessment of hand and/or feet (hfPGA).
For all reviewed studies, the intervention applied was 40 mg of subcutaneous
ADA administered every two weeks. All three studies compared the effects of ADA to
the placebo with the outcomes measured based on the reduction of baseline PASI and
hfPGA scores, and adverse drug reactions in regards to patient safety during trials.
Articles were researched by the author of this review via Ebscohost, and PubMed
databases and were selected based on their relevance to the clinical question. The
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outcome measured included patient oriented evidence that matters (POEMS). All three
articles were written in the English language between 2010 and 2013, and published as
peer reviewed journals. Key words entered in the databases included “adalimumab”,
“psoriasis”, “treatment outcomes”, and “biological therapy”.
The studies selected for this EBM review included the following inclusion
criteria: all studies were a form of primary research (RCTs, retrospective studies, cohort
studies etc.), all included POEMS, and all evaluated the efficacy of ADA on moderate to
severe chronic plaque psoriasis as an outcome measure. The exclusion criteria included
patients under the age of 18 years, those with mild disease (PASI < 3), nail psoriasis, and
patients who had psoriasis on the hands and feet only. If a patient had lesions on the
hands and feet, evidence of psoriatic disease had to identify in at least one other
cutaneous region to be included in this study.
Poulin et al.1 excluded all patients who have been previously treated with ADA,
and Thaci et al.5 excluded patients who had been treated with ADA or
calcipotriol/betamethasone (C/B) two weeks prior to baseline study visits. Furthermore,
patients were excluded if treated with systemic or topical corticosteroids within 4 weeks
and 2 weeks respectively. The statistics used in these three trials included Control Event
Rate (CER), Experimental Event Rate (EER), p-value, Numbers Needed to Treat (NNT),
Relative Benefit Increase (RBI), and Absolute Benefit Increase (ABI).
Table 1: Demographics and Characteristics of Included Studies
Study

Type

#Pts

Poulin1

Double
blind
RCT

72

Age
(yrs)
18+

Inclusion
Criteria
Adult
(18+) men
and
women

Exclusion
Criteria
-Pts <18 y/o.
-Pts with nail
psoriasis.
Previous tx

W/D

Interventions

9

ADA 40mg
SQ every 2
weeks

Audia, ADA and Psoriasis 5

Thaci4

Double
blind
RCT

730

18+

Sanche
z5

Retrosp
ective
study

84

18+

with
MSPP for
at least 6
months
and a
baseline
score of 3
on
hfPGA.
-chronic
plaque
psoriasis
for at least
6 months.
PASI >10
and >10%
BSA
affected.
-Failure
therapy
with
another
biologic
or
systemic
PASI >3,
psoriatic
arthritis,
nail
psoriasis.

with ADA.
Palmoplantar
pustulosis or
other active
skin
infection.
Prior ADA
tx, topical
C/B therapy
2 wks prior
to baseline
study. Tx
with
systemic or
topical
steroid 4 and
2 wks prior,
systemic
disease that
could alter tx
(TB, CA,
HCV)
PASI <3 if tx
prior with
topical drugs

0

ADA 80 mg
week 0, 40mg
every other
week from
week 1-15

0

ADA 40 mg
SQ every 2
weeks.

OUTCOMES MEASURED
All three studies evaluated the effects of patient baseline characteristics on
efficacy of ADA treatment of chronic cutaneous plaque psoriasis. In Poulin et al.1,
patients with moderate to severe plaque psoriasis of the hands and feet with at least one
other cutaneous lesion were randomized 2:1 to ADA or placebo during the 16 week,
double blind period. The primary endpoint was percentage of patients achieving an
hfPGA of clear/almost clear at week 16. In the 16 week randomized, vehicle controlled
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study conducted by Thaci et al.5, patients were randomized in a 1:1 ratio to receive ADA
with calcipotroil hydrate plus betamethasone dipropionate topical ointment (C/B) or an
identically supplied and formulated drug-free vehicle. The primary goal was 75%
improvement from baseline in the PASI at the conclusion of the study. Sanchez-Regana
et al.6 performed a retrospective study on 84 patients with moderate-severe chronic
psoriasis between January 2006 and January 2009. The primary endpoint of the
retrospective study was to evaluate the patients who achieved 75% improvement in PASI
using ADA compared to classical treatment at 24 weeks.
RESULTS
All studies were performed using the methods outlined above. In the study
conducted by Poulin et al.1, 72 patients were analyzed. 49 patients received ADA and 23
received placebo. Due to investigator non-compliance at one study center, all 9 patients at
that center were excluded from all analysis. Post hoc analyses reported in this study
included age, gender, weight, disease distribution and disease duration. A significantly
greater percentage of ADA treated patients achieved an hfPGA score of clear/almost
clear at week 16 compared to patients treated with placebo (P = 0.014) outlined in Table
2. The study concluded that effectiveness of ADA treatment was similar in all age groups
and gender. However, patients who weighed less than 88 kg had a significant clinically
greater hfPGA response (38.1%) compared to patients greater than 88 kg (25.0%) 1.
Interestingly, patients treated with ADA demonstrated improvement in both shorter and
longer duration psoriasis but patients with longer duration disease (>4.7 years) showed a
better hfPGA response (40%) compared to shorter duration patients (20.8%) 1.
Table 2: Efficacy of ADA on Hand and Foot Psoriasis with Evidence of Cutaneous
Disease
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Proportion of
Proportion of
patients
patients having
having
symptom
symptom
improvement
improvement
with ADA
with placebo
(EER)
(CER)
(4.3%) 0.043 (30.6%) 0.306

Relative
benefit
increase
(RBI)
EER- CER
CER

6.11

Absolute benefit
increase (ABI)

Number needed to
treat (NNT)

EER - CER

1/ABI

0.263
P = 0.014

4

In the Thaci et al.5 study, a total of 730 patients participated with 366 patients
receiving ADA + C/B and 364 patients receiving ADA + vehicle. Initially, PASI
responses were higher in the combination therapy (40.7%) compared to ADA monotherapy (32.4%) after four weeks (P = 0.021) 5. After week 4, the trend was towards
higher response rates with ADA mono-therapy, with no statistical difference in the PASI
75 response at week 16 (64.8% for ADA + C/B, 70.9% for ADA, P = 0.086) 5.
Interestingly, at week 16, patients receiving ADA as mono-therapy achieved PASI
responses of 90% improvement (50%) compared to ADA + C/B (38%, P =0.002) 5. Table
3 summarizes the efficacy of the Thaci et al.5 study in patients who achieved PASI 90.
Table 3: Efficacy of ADA with Topical C/B compared to ADA mono-therapy
Relative
Absolute
Number needed
benefit
benefit
to treat (NNT)
increase (RBI)
increase
(ABI)
CER
EER
EER- CER
EER - CER
1/ABI
CER
(38.8%) 0.388 (50%) 0.50
0.289
0.112
9
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p-value = 0.002

In the Sanchez-Regana et al.6 study, 84 patients with moderate to severe psoriasis
where reviewed in retrospective form. They concluded that the rate of response to
treatment in patients with cutaneous disease achieved a PASI 75 with ADA therapy
(80%) compared classical treatment (53.1%) at 24 weeks (P = 0.01). Table 4 summarizes
the effectiveness of ADA compared to classical treatment of plaque psoriasis.
Table 4: Efficacy of ADA Therapy for Moderate-Severe Plaque Psoriasis
Relative
Absolute
Number needed
benefit
benefit
to treat (NNT)
increase (RBI)
increase
(ABI)
CER
EER
EER- CER
EER - CER
1/ABI
CER
(53.1%)
(80%) 0.80
0.51
0.269
4
0.531
P < 0.01

DISCUSSION
The Poulin et al.1 study demonstrated that patient demographics and disease
characteristic such disease duration did not effect the efficacy of ADA for the treatment
of moderate to severe plaque psoriasis. All patients demonstrated improved responses
following ADA therapy, but greater response to treatment was seen in patients that had
longer disease duration and lighter body weight. The NNT is calculated to determine the
number of patients that needed to receive ADA in order to benefit one patient. Only 4
patients needed to be treated to have one with symptom improvement compared to
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control. The major limitation of this study was patient sample size. In the Thaci et al.5
study, greater efficacy at week 16 was not significant with the combination of ADA and
topical C/B compared to ADA mono-therapy. However, since there was statically
significant improvement at week 4 using the ADA combination therapy, this suggests
that combination therapy may be useful when a rapid response is warranted.
Alternatively, both therapies were effective in achieving a PASI 75, but ADA
monotherapy was superior in attaining PASI >75 when compared to combination
therapy. The author of this review elected to use data representing a PASI 90 due to its
statistical significance (P = 0.002) compared to PASI 75 data (P = 0.086). Thaci et al.
identified that patient non compliance may have impacted their study findings. The
Sanchez-Regana et al.6 retrospective study found that biological therapy (adalimumab,
infliximab etc.) were most effective in treating both cutaneous and nail psoriasis
especially in moderate to severe disease. Furthermore, biologic therapy was effective in
treating associated comorbidities such has psoriatic arthritis. The major limitation to the
Sanchez-Regana et al. study was that it was a retrospective study.
CONCLUSION
Psoriasis has a negative impact on patient quality of life due to its visibility and
associated comorbidities. Based on this EBM review, it can be concluded that ADA is
effective in treating moderate to severe chronic plaque psoriasis in adults. All three
studies noted that treatment regimens were well tolerated with minimal adverse reactions.
Additionally the Thaci et al. study concluded that adjunctive topical therapy with a TNF
inhibitor can be a safe and effective treatment option in patients who have moderate to
severe plaque psoriasis. Future studies may be warranted to investigate the effects of
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using a TNF inhibitor to treat the associated comorbidities of psoriasis such as psoriatic
arthritis, malignancies, and heart disease. Although ADA was deemed safe in the
research conducted for this review, adverse effects related to long-term application of
ADA beyond 16 weeks may warrant investigation due to the drugs ability to eliminate an
important inflammatory marker of our innate immune system.
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